嗅神经母细胞瘤：玛格丽特公主医院的经验
Esthesioneuroblastoma: The Princess Margaret Hospital experience.
作者信息
Bachar Gideon, Goldstein David P, Shah Manish, Tandon Asheesh, Ringash Jolie, Pond Gregory, Gullane Patrick J, Perez-Ordonez Bayardo, Gilbert Ralph W, Brown Dale H, Gentili Fred, O'Sullivan Brian, Irish Jonathan C
机构信息
Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
出版信息
Head Neck. 2008 Dec;30(12):1607-14. doi: 10.1002/hed.20920.
BACKGROUND
Esthesioneuroblastoma is rare. The aim of the study was to review our experience and to evaluate the staging system and treatment that best correlates with the patient outcome.
METHODS
Thirty-nine patients were identified between 1972 and 2006.
RESULTS
At presentation 10% had cervical metastases. None had distant metastasis. Five were treated with surgery, 2 with chemotherapy, 1 with radiotherapy, and 30 with surgery and radiation. Local disease control was 82.6% at 5 years. Recurrence was seen in 33% with local and regional disease recurrence at 15% and 18%, respectively. The 5- and 10-year overall survival rates were 87.9% and 69.2%, respectively. Dulguerov classification correlated most closely to survival and recurrence.
CONCLUSIONS
Dulguerov classification best correlates with the patient's outcome. A combined approach is the preferred treatment. It makes no difference whether radiotherapy is given pre or postsurgical resection. Recurrence can occur even 15 years after treatment. Therefore, long-term follow-up is essential.
背景
嗅神经母细胞瘤较为罕见。本研究的目的是回顾我们的经验，并评估与患者预后最相关的分期系统和治疗方法。
方法
确定了1972年至2006年间的39例患者。
结果
初诊时10%的患者有颈部转移。无远处转移。5例接受手术治疗，2例接受化疗，1例接受放疗，30例接受手术和放疗。5年时局部疾病控制率为82.6%。局部和区域疾病复发率分别为15%和18%，总复发率为33%。5年和10年总生存率分别为87.9%和69.2%。杜尔格罗夫分类与生存和复发的相关性最为密切。
结论
杜尔格罗夫分类与患者预后的相关性最佳。联合治疗是首选治疗方法。术前或术后放疗并无差异。甚至在治疗15年后仍可能发生复发。因此，长期随访至关重要。
Zotero 插件